Business Communication for Success - GVSU Edition

About the GVSU Edition This text is an adaption of Business Communication for Success, an open textbook produced by the University of Minnesota Libraries Publishing in 2015. Chapters 9, 18, and 20 of Business Communication for Success: GVSU Edition were revised and rewritten by student authors in 2017, as part of a course in the Writing Department at Grand Valley State University. All other chapters retain the content and formatting of previous editions. Note about the 2015 edition: The edition produced by the University of Minnesota Libraries Publishing University of Minnesota Libraries Publishing was itself adapted from a work distributed under a Creative Commons license (CC BY-NC-SA) in 2010 by a publisher who requested that they and the original author not receive attribution. This adaptation reformatted the original text, and replaced some images and figures to make the resulting whole more shareable. The 2015 adaptation did not significantly alter or update the original 2010 text.https://scholarworks.gvsu.edu/books/1013/thumbnail.jp

Multi-Institutional Implementation of Clinical Decision Support for APOL1, NAT2, and YEATS4 Genotyping in Antihypertensive Management

(1) Background: Clinical decision support (CDS) is a vitally important adjunct to the implementation of pharmacogenomic-guided prescribing in clinical practice. A novel CDS was sought for the APOL1, NAT2, and YEATS4 genes to guide optimal selection of antihypertensive medications among the African American population cared for at multiple participating institutions in a clinical trial. (2) Methods: The CDS committee, made up of clinical content and CDS experts, developed a framework and contributed to the creation of the CDS using the following guiding principles: 1. medical algorithm consensus; 2. actionability; 3. context-sensitive triggers; 4. workflow integration; 5. feasibility; 6. interpretability; 7. portability; and 8. discrete reporting of lab results. (3) Results: Utilizing the principle of discrete patient laboratory and vital information, a novel CDS for APOL1, NAT2, and YEATS4 was created for use in a multi-institutional trial based on a medical algorithm consensus. The alerts are actionable and easily interpretable, clearly displaying the purpose and recommendations with pertinent laboratory results, vitals and links to ordersets with suggested antihypertensive dosages. Alerts were either triggered immediately once a provider starts to order relevant antihypertensive agents or strategically placed in workflow-appropriate general CDS sections in the electronic health record (EHR). Detailed implementation instructions were shared across institutions to achieve maximum portability. (4) Conclusions: Using sound principles, the created genetic algorithms were applied across multiple institutions. The framework outlined in this study should apply to other disease-gene and pharmacogenomic projects employing CDS

Increase Engagement and Success in the Classroom Using the Vision Board Method Academia.

The Vision Board Method allows the student to take control of their academic destiny by creating a vision per course, developing a blueprint for success incorporating strategies for achieving their goals. During this process, students are taught how to take their vision and turn it into success by goal setting, planning and research using information literacy strategies to visualize their success in the course and in college. Students are given clear instructions with a rubric that explains the assignment. The students will analyze the syllabus for the class and create a vision board that inspires them into action using the proprietary Vision Board Method Academia. Students will combine their passion and goals in life, with what it takes to be successful in that class and then research what they need to merge the two together. Throughout the course, checkpoints are built in to make sure the roadmaps that students developed are actually effective in successfully completing the course

Collaboration: Embedding Librarians, Faculty and Students into the Information Literacy Program

See presentation description

Web-Scale Discovery: Illusion or Reality?

See presentation description

DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity

Contains fulltext : 118242.pdf (publisher's version ) (Open Access)BACKGROUND: Gene-based vaccination using prime/boost regimens protects animals and humans against malaria, inducing cell-mediated responses that in animal models target liver stage malaria parasites. We tested a DNA prime/adenovirus boost malaria vaccine in a Phase 1 clinical trial with controlled human malaria infection. METHODOLOGY/PRINCIPAL FINDINGS: The vaccine regimen was three monthly doses of two DNA plasmids (DNA) followed four months later by a single boost with two non-replicating human serotype 5 adenovirus vectors (Ad). The constructs encoded genes expressing P. falciparum circumsporozoite protein (CSP) and apical membrane antigen-1 (AMA1). The regimen was safe and well-tolerated, with mostly mild adverse events that occurred at the site of injection. Only one AE (diarrhea), possibly related to immunization, was severe (Grade 3), preventing daily activities. Four weeks after the Ad boost, 15 study subjects were challenged with P. falciparum sporozoites by mosquito bite, and four (27%) were sterilely protected. Antibody responses by ELISA rose after Ad boost but were low (CSP geometric mean titer 210, range 44-817; AMA1 geometric mean micrograms/milliliter 11.9, range 1.5-102) and were not associated with protection. Ex vivo IFN-gamma ELISpot responses after Ad boost were modest (CSP geometric mean spot forming cells/million peripheral blood mononuclear cells 86, range 13-408; AMA1 348, range 88-1270) and were highest in three protected subjects. ELISpot responses to AMA1 were significantly associated with protection (p = 0.019). Flow cytometry identified predominant IFN-gamma mono-secreting CD8+ T cell responses in three protected subjects. No subjects with high pre-existing anti-Ad5 neutralizing antibodies were protected but the association was not statistically significant. SIGNIFICANCE: The DNA/Ad regimen provided the highest sterile immunity achieved against malaria following immunization with a gene-based subunit vaccine (27%). Protection was associated with cell-mediated immunity to AMA1, with CSP probably contributing. Substituting a low seroprevalence vector for Ad5 and supplementing CSP/AMA1 with additional antigens may improve protection. TRIAL REGISTRATION: ClinicalTrials.govNCT00870987